Nektar Therapeutics (NKTR) Cash & Current Investments (2010 - 2026)

Nektar Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $568.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 160.07% year-over-year to $568.6 million; the TTM figure through Mar 2026 stood at $568.6 million (up 160.07% YoY), while the FY2025 annual figure was $245.8 million, down 3.71% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $568.6 million, up from $245.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $667.0 million in Q1 2022, with the low at $175.9 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $303.6 million (2023), against an average of $377.6 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments sank 40.68% in 2022, then surged 160.07% in 2026.
• Nektar Therapeutics' Cash & Current Investments stood at $505.0 million in 2022, then sank by 39.88% to $303.6 million in 2023, then retreated by 15.94% to $255.2 million in 2024, then retreated by 3.71% to $245.8 million in 2025, then surged by 131.37% to $568.6 million in 2026.
• Business Quant data shows NKTR's Cash & Current Investments at $568.6 million in Q1 2026, $245.8 million in Q4 2025, and $270.2 million in Q3 2025.